Financials

	2025 *	2026 *
Net sales	38M 1.2M 1.02M 932K 882K 1.64M 109M 1.71M 10.83M 4.29M 52.38M 4.5M 4.41M 189M	6.03B 191M 161M 148M 140M 260M 17.27B 272M 1.72B 680M 8.31B 715M 700M 29.93B
Net income	-691M -21.84M -18.49M -16.94M -16.05M -29.8M -1.98B -31.15M -197M -77.95M -952M -81.9M -80.21M -3.43B	3.66B 116M 97.94M 89.76M 85.02M 158M 10.48B 165M 1.04B 413M 5.05B 434M 425M 18.17B
Net Debt	-6.26B -198M -167M -153M -145M -270M -17.92B -282M -1.78B -706M -8.63B -742M -727M -31.06B	-8.42B -266M -225M -206M -195M -363M -24.1B -379M -2.4B -949M -11.6B -997M -977M -41.76B

More financial data * Estimated data

Company Profile

Employees

-

Sector

Pharmaceuticals

Calendar

04-08 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
06/02/26	171.00 NT$	+2.40%	9,887,513
05/02/26	167.00 NT$	-1.18%	5,336,097
04/02/26	169.00 NT$	+0.90%	5,888,777
03/02/26	167.50 NT$	+2.13%	5,038,877
02/02/26	164.00 NT$	-0.91%	10,981,510

End-of-day quote Taiwan S.E., February 05, 2026

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

1

Last Close Price

171.00TWD

Average target price

240.00TWD

Spread / Average Target

+40.35%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

End-of-day quote Taiwan S.E. Other stock markets 06/02/2026			5-day change	1st Jan Change
171.00 ^TWD	+2.40%		+3.95%	+10.32%

12-25	Caliway Biopharmaceuticals Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies	CI
12-22	Tranche Update on Caliway Biopharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on October 13, 2025.	CI

Capitalization	265B 8.38B 7.09B 6.5B 6.15B 11.43B 759B 11.95B 75.52B 29.9B 365B 31.41B 30.77B 1,315B	P/E ratio 2025 *	-389x	P/E ratio 2026 *	72.5x
Enterprise value	259B 8.18B 6.92B 6.35B 6.01B 11.16B 741B 11.67B 73.74B 29.19B 357B 30.67B 30.04B 1,284B	EV / Sales 2025 *	6,810x	EV / Sales 2026 *	42.5x
Free-Float	-	Yield 2025 *	-	Yield 2026 *	0.42%

12-25	Caliway Biopharmaceuticals Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies	CI
12-22	Tranche Update on Caliway Biopharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on October 13, 2025.	CI
12-16	Caliway Biopharmaceuticals Presents Preclinical Research Supporting A Multi-Mechanism Approach to Weight Management At TMASO 2025	CI
12-10	Caliway Biopharmaceuticals Co., Ltd.'s Equity Buyback announced on October 13, 2025, has expired with 901,000 shares, representing 0.06% for TWD 130.52 million.	CI
11-10	Caliway Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-10	Caliway Biopharmaceuticals Books Nine-Month Loss of NT$432 Million; Shares Drop 5%	MT
11-10	Caliway Biopharmaceuticals Skips Q3 Dividends; Shares Drop 4%	MT
12/10/25	Caliway Biopharmaceuticals Co., Ltd. authorizes a Buyback Plan.	CI
12/10/25	Caliway Biopharmaceuticals Co., Ltd. announces an Equity Buyback for 1,800,000 shares, for TWD 450 million.	CI
22/09/25	Caliway Biopharmaceuticals Co., Ltd.(TWSE:6919) added to FTSE All-World Index	CI
11/09/25	Caliway Biopharmaceuticals Denies Media Report Claiming Poor Phase 3 Results of Weight Loss Drug; Shares Drop 10%	MT
12/08/25	Caliway Biopharmaceuticals Receives Approval from Health Canada	CI
12/08/25	Caliway Biopharmaceuticals Gets Canadian Regulator's Nod for Fat-Reduction Drug Trial	MT

12-25	Caliway's Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies	PR
12-16	Caliway Biopharmaceuticals Presents Preclinical Research Supporting a Multi-Mechanism Approach to Weight Management at TMASO 2025	PR
12/08/25	Caliway Met Dual Milestones with MSCI Global Standard Index Inclusion, and Health Canada has Approved the Phase 3 SUPREME-01 Study	PR
28/07/25	Caliway Announces FDA Clearance of IND Application for CBL-514 to Proceed with SUPREME-01, the First Global Pivotal Phase 3 Study for Reducing Abdominal Subcutaneous Fat	PR
10/06/25	Caliway to Present First Preclinical Data on CBL-514 for GLP-1 Weight Rebound Management at BIO 2025	PR

Caliway Biopharmaceuticals Co., Ltd. Share Price

Equities

6919

TW0006919004

Pharmaceuticals

Valuation: Caliway Biopharmaceuticals Co., Ltd.

Chart: Caliway Biopharmaceuticals Co., Ltd.

Latest news: Caliway Biopharmaceuticals Co., Ltd.

Press Releases: Caliway Biopharmaceuticals Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Caliway Biopharmaceuticals Co., Ltd.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

1 day	+2.40%
1 week	+3.95%
Current month	+3.32%
1 month	+11.40%
3 months	+17.12%
6 months	+41.32%
Current year	+10.32%

1 week	162	174.5
1 month	141	181
Current year	141	181
1 year	54.1	277
3 years	9.35	277
5 years	5.55	277
10 years	5.55	277

Manager	Title	Age	Since
Vivian Ling CEO	Chief Executive Officer	-	-
Antony Hsu PSD	President	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
CALIWAY BIOPHARMACEUTICALS CO., LTD.	+2.40%	+3.95%	+131.08%	+1,733.78%	8.17B
ELI LILLY AND COMPANY	+3.66%	+2.03%	+21.58%	+213.39%	914B
JOHNSON & JOHNSON	+0.93%	+5.61%	+56.34%	+46.91%	573B
ABBVIE INC.	+2.01%	+0.19%	+15.78%	+54.07%	387B
ROCHE HOLDING AG	-0.64%	+2.71%	+22.35%	+26.23%	368B
MERCK & CO., INC.	+1.82%	+10.57%	+38.48%	+17.21%	297B
ASTRAZENECA PLC	+0.89%	+4.78%	+26.77%	+33.33%	294B
NOVARTIS AG	+0.57%	+4.97%	+21.69%	+50.82%	293B
NOVO NORDISK A/S	+5.29%	-20.22%	-52.30%	-37.23%	197B
AMGEN INC.	+4.49%	+12.41%	+29.06%	+57.61%	198B
Average	+1.80%	+1.14%	+31.08%	+219.61%	352.85B
Weighted average by Cap.	+1.58%	+1.31%	+25.08%	+85.17%